Health In Tech, Inc. Class A earnings date
Want to see HIT full AI Analyst Report?
Health In Tech, Inc. Class A (HIT) Q3 2026 Earnings Report
HIT Q3 2026 EPS Results
- Actual EPS
- -$0.11
- Consensus EPS
- -$0.05
- Beat/Miss
- Missed by -$0.06
- One Year Ago EPS
- $0.01
HIT Q3 2026 Revenue Results
- Actual Revenue
- $6.59M
- Expected Revenue
- $7.96M
- Beat/Miss
- Missed by -$1.37M
- YoY Revenue Growth
- -22.41%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/12/2026
- Time
- After Close
- Conference Call
- Thursday, November 12, 2026
Health In Tech, Inc. Class A's next earnings date is estimated for March 22, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call presented a mixed, transitional outlook. Health In Tech highlighted a growing distribution network, substantial pipeline and contracted-revenue visibility, improving operating cash flow, a stronger cash position and multiple product initiatives targeted for commercialization. However, these positives were offset by declining reported revenue, gross-margin compression, significant credit-loss provisions, negative EBITDA and net losses, delayed commercialization, low historical pipeline conversion and the absence of finalized 2027 guidance. Management expressed confidence in the opportunity but acknowledged that execution and conversion remain the central challenges.
Health In Tech updated its full year 2026 revenue outlook to approximately $30 million and said gross margin would maintain in the range of 45% to 50% in the coming quarters; its $153.8 million pipeline carries an expected conversion rate of 3% to 7%, meaning it would generate $9.3 million to $10.7 million revenue for the 3 months, while approximately 70% of the approximately $150 million potential annualized revenue pipeline was associated with January 1, 2027. The company’s goal is to complete the first end-to-end Three-Year Rate Stabilization Program launch by the end of 2026, launch the HitRix minimum viable product in the first quarter of 2027, and launch an initial HITChain minimum viable product during the second half of 2027; management said HitRix is probably Q2 opportunity at the earliest, HITChain is a second half 2027 opportunity, and expected further improvement in operating cash flow as it commercializes the new service and product in 2027, but it is not presenting a finalized 2027 plan or revenue outlook today.
- Leadership Transition Supports Execution FocusHealth In Tech separated the Executive Chairman and CEO roles, with Tim Johnson continuing to focus on long-term strategy, technology innovation and product development, while Sanjay Shrestha leads day-to-day operations, commercial execution, organizational scaling and potential strategic acquisitions or partnerships.
- Investment in Technology, Distribution and New CapabilitiesManagement described 2026 as a year of investment and capability building, including expansion of the sales and distribution network, stronger relationships with brokers, carriers, MGUs and strategic partners, and continued development of the underlying marketplace technology. The company also advanced the Three-Year Rate Stabilization Program, HitRix and HITChain.
- Significant Revenue PipelineAs of October 30, 2026, the platform had approximately $150 million in potential annualized revenue associated with quoting activity for policies with anticipated November 2026, December 2026 and January 2027 effective dates, with approximately 70% associated with January 1, 2027. Separately, the CFO reported $156.4 million of pipeline revenue in quoting or binding stages, plus policies contracted since quarter end, with an expected conversion rate of 3% to 7% for the remaining $153.8 million.
- Contracted Revenue VisibilityContracted revenue totaled $32.7 million for the first nine months of 2026, including $24.4 million recognized as GAAP revenue through September 30. The company stated that it had secured $30.5 million of 2026 revenue, including $6.1 million scheduled for recognition in the fourth quarter, with $2.2 million expected to flow into 2027.
- Expanded Distribution NetworkThe ecosystem reached 984 brokers, third-party administrators and agency partners as of September 30, 2026, compared with 849 a year earlier, representing approximately 15.9% year-over-year growth, or almost 16%.
- Core SMR Fee Revenue Remained StableSMR fee revenue was essentially unchanged year-over-year for the first nine months, at $20.04 million compared with $19.9 million in the prior-year period. Management said the largest revenue line held essentially steady despite the carrier transition.
- Three-Year Rate Stabilization Program ProgressThe company secured a client under a medical stop-loss agreement and completed the insurance portion of the initial Three-Year Rate Stabilization Program transaction. Capital-market work was progressing, and management's goal was to complete the first end-to-end program launch by the end of 2026.
- HitRix Commercialization PlanHitRix is an AI-powered large-group insurance marketplace designed to automate document intelligence, quoting, underwriting submissions and placement workflows. The company is targeting a minimum viable product launch in the first quarter of 2027 and plans to expand capabilities and commercial adoption throughout the year.
- HITChain Development RoadmapHITChain is designed to use blockchain-enabled verification and AI-powered automation for claims administration, reconciliation and provider payments. The company is targeting an initial minimum viable product launch during the second half of 2027.
- Improving Operating Cash FlowOperating cash usage improved sequentially from negative $3.3 million in the first quarter to negative $2.9 million in the second quarter and negative $1.0 million in the third quarter, representing approximately a 68% reduction from the first quarter to the third quarter. Management attributed the third-quarter improvement to accounts receivable and accounts payable-related working-capital improvements.
- Stronger Cash PositionCash and cash equivalents ended the quarter at $10.1 million, compared with $7.7 million at the end of 2025, leaving the company approximately $2.5 million higher than at the beginning of the year despite $7.3 million of operating cash use and $1.8 million of software investment during the first nine months.
- General and Administrative Cost DisciplineThird-quarter general and administrative expenses were $3.1 million compared with $3.5 million a year earlier, while nine-month G&A expenses were $10.1 million compared with $10.5 million. Management attributed the reduction to disciplined cost management and workforce optimization.
- Broader Strategic Growth OpportunitiesManagement plans to evaluate strategic acquisitions, investments and partnerships that could complement the technology platform, strengthen the market position, expand capabilities or accelerate growth, while emphasizing strategic fit, execution risk, capital requirements and long-term shareholder value.
HIT Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 22, 2027 | 2026 (Q4) | -0.05- | -0.01 | ― | ― |
| Nov 12, 2026 | 2026 (Q3) | -0.05-0.11 | 0.01 | -1200.00% (-0.12) | |
| Aug 13, 2026 | 2026 (Q2) | -0.03-0.04 | 0.01 | -500.00% (-0.05) | |
| May 13, 2026 | 2026 (Q1) | -0.03-0.03 | 0.01 | -300.00% (-0.04) | |
| Mar 25, 2026 | 2025 (Q4) | -0.01-0.01 | -0.01 | 0.00% (+0.00) | |
| Nov 10, 2025 | 2025 (Q3) | 0.010.01 | 0.01 | 42.86% (+0.00) | |
| Jul 21, 2025 | 2025 (Q2) | 0.010.01 | 0.01 | 66.67% (+0.00) | |
| Apr 14, 2025 | 2025 (Q1) | 0.010.01 | 0 | 650.00% (+0.01) | |
| Mar 17, 2025 | 2024 (Q4) | ―-0.01 | 0.02 | -155.56% (-0.03) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


